You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Regulatory clearance of a rehabilitation system for individuals with upper limb loss
SBC: INFINITE BIOMEDICAL TECHNOLOGIES, LLC Topic: 105ABSTRACT Our work to date has resulted in the development of several technologies focused on improving the lives of individuals with upper-limb loss (ULL). First, our Sense pattern recognition control system (and associated Element low-profile surface EMG electrodes and FlexCell flexible lithium-polymer batteries) can interface with most myoelectric hands, wrists, and elbows on the market. Second, ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of optimized adeno-associated viral capsids for muscle gene therapy
SBC: AAVOGEN INC Topic: NIAMSPROJECT SUMMARY. Gene therapeutics offer hope to many patients with rare muscle and neuromuscular diseases. Despite some early successes, several serious off-target safety concerns have compromised their development due to hepatic toxicities and related immune responses to the adeno-associated viral (AAV) vectors. The generation of novel capsids with superior muscle specificity could, therefore, r ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Plans4Care: Personalized Dementia Care On-Demand
SBC: Plans4Care INC Topic: RPROJECT ABSTRACT Although rt11 million family/friends are caregivers to rt6 million people with Alzheimer's Disease (AD) and AD- Related Dementias (AD/ADRD), they do not typically receive personalized education, strategies and support to manage their own wellbeing and complex dementia-related symptoms. Lack of personalized care contributes to $321 billion annually in AD/ADRD care costs. In respons ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Advanced Prediction of Emerging Respiratory Decline with the Linshom Continuous Predictive Respiratory Sensor (CPRS)
SBC: LINSHOM MEDICAL INC Topic: NHLBIAbstract: This Fast-track SBIR application will fund and enable a new approach to respiratory monitoring, continuous predictive respiratory monitoring (CPRM), that stands to reduce morbidity and mortality due to respiratory compromise, while reducing health care system costs. Current devices and systems (human and machine) for respiratory monitoring are responsive by sounding a warning alarm when ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Amino Acids and Pediatric Hepatic Steatosis
SBC: THE AMINO COMPANY LLC Topic: 3007. Project Summary/Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in North America (1). Hepatic steatosis (HS) is the hallmark of NAFLD (2). NAFLD may transition in sub-groups to chronic inflammation (non- alcoholic steatohepatitis, NASH), and ultimately to cirrhosis. HS is prevalent in all stages of NAFLD. 3-10% of all children in the US and 40-70% of obese ch ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
RestEaze: A Novel Wearable Device and Mobile Application to Improve the Diagnosis and Management of Restless Legs Syndrome in Pediatric Patients with Attention Deficit/Hyperactivity Disorder
SBC: TANZEN MEDICAL, INC. Topic: 104Project Abstract Millions of pediatric patients with attention-deficit/hyperactivity disorder (ADHD) suffer from sleep disturbances that significantly degrade their quality of life and amplifies the heavy emotional and financial burden on caregivers. Restless Legs Syndrome (RLS) is a likely (and treatable) factor for the sleep disturbance in these patients. Oral iron therapy has been shown to impr ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Highly Multiplexed Single Molecule Tethering
SBC: SCANOGEN INC. Topic: NIAIDHighly Multiplexed Single Molecule Tethering Summary Bloodstream infections in patients with sepsis symptoms should be promptly treated with antibiotics; however, the time required to identify pathogens using methods based on blood culture is a major obstacle to timely effective antimicrobial therapy. The development of a comprehensive molecular assay capable of identifying microbes directly from ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of an innovative approach for in situ treatment of PCB impacted sediments by microbial bioremediation
SBC: REMBAC ENVIRONMENTAL, LLC Topic: 143PROJECT SUMMARY Polychlorinated biphenyls (PCBs) are one of the most problematic of legacy pollutants. Persistent and mobile in the environment, PCBs are largely ubiquitous in depositional sediments of aquatic systems in industrial regions of the United States. Their relatively high toxicity and bioaccumulation potential cause elevated risk to both human and ecological receptors. As such, PCBs are ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients
SBC: Up Therapeutics LLC Topic: NCIEpithelial ovarian cancer (EOC) is the most lethal gynecological malignancy despite aggressive surgery and toxic chemotherapies. More effective and safer targeted drugs are urgently needed to address this unmet medical need. Compared to normal tissues, EOC exhibits aberrant proteasome function that triggers accumulation of high molecular weight polyubiqutinated and misfolded protein aggregates. Be ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis
SBC: Rise Therapeutics, LLC Topic: NIAProject Summary Our goal is to develop a novel, immunological-directed L. lactis probiotic-based therapeutic for the treatment of rheumatoid arthritis (RA). RA is a chronic, systemic inflammatory disorder affecting up to 1% of the US population1, 2. While many organs are affected in RA, the synovial joints are primarily afflicted with debilitating inflammation. Approximately half of all RA patient ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health